A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
- Author
- LEE, J.-L1 ; KANG, Y.-K1 ; RYU, M.-H1 ; CHANG, H. M1 ; KIM, T.-W1 ; BAEK, J. H9 ; MIN, Y. J9 ; KANG, H. J2 ; LEE, K.-H3 ; ZANG, D. Y4 ; RYOO, B.-Y2 ; KIM, J. G5 ; PARK, S. R6 ; KANG, W. K7 ; SHIN, D. B8
[1] Department of internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea, Republic of
[2] Korea Institute of Radiological and Medical Science, Seoul 139-706, Korea, Republic of
[3] Yeungnam University Medical Center, Yeungnam University School of Medicine, Daegu 705-030, Korea, Republic of
[4] Hallym University Medical Center, Hallym University College of Medicine, Anyang 431 -070, Korea, Republic of
[5] Kyungpook National University Hospital, Kyungpook National University College of Medicine, Daegu 700-721, Korea, Republic of
[6] National Cancer Institute, Goyang 410-769, Korea, Republic of
[7] Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea, Republic of
[8] Gacheon Medical School Gil Medical Center, Gacheon University of Medical Science, Incheon 405-760, Korea, Republic of
[9] Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 682-060, Korea, Republic of - Source
British journal of cancer. 2008, Vol 99, Num 4, pp 584-590, 7 p ; ref : 1 p
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- S-1 capecitabine efficacy elderly gastric cancer safety
- Keyword (fr)
- Anticancéreux Cancer de l'estomac Cancérologie Capécitabine Efficacité traitement Essai clinique phase II Essai clinique Etude comparative Inopérable Métastase Personne âgée Promédicament Récidive Stade avancé Traitement de première intention Cancer Dérivé de la fluoropyrimidine Homme Pathologie de l'appareil digestif Pathologie de l'estomac Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Antineoplastic agent Stomach cancer Cancerology Capecitabine Treatment efficiency Phase II trial Clinical trial Comparative study Unresectable Metastasis Elderly Prodrug Relapse Advanced stage First line treatment Cancer Fluoropyrimidine derivatives Human Digestive diseases Gastric disease Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del estómago Cancerología Capecitabina Eficacia tratamiento Ensayo clínico fase II Ensayo clínico Estudio comparativo Inoperable Metástasis Anciano Promedicamento Recaida Estadio avanzado Tratamiento de primera línea Cáncer Fluoropirimidina derivado Hombre Aparato digestivo patología Estómago patología Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20656328
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6604536 
https://dx.doi.org/10.1038/sj.bjc.6604536
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"584\";s:8:\"\u0000*\u0000epage\";s:3:\"590\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"LEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J.-L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"KANG, Y.-K\";i:1;s:9:\"RYU, M.-H\";i:2;s:11:\"CHANG, H. M\";i:3;s:9:\"KIM, T.-W\";i:4;s:10:\"BAEK, J. H\";i:5;s:9:\"MIN, Y. J\";i:6;s:10:\"KANG, H. J\";i:7;s:9:\"LEE, K.-H\";i:8;s:10:\"ZANG, D. Y\";i:9;s:10:\"RYOO, B.-Y\";i:10;s:9:\"KIM, J. G\";i:11;s:10:\"PARK, S. R\";i:12;s:10:\"KANG, W. K\";i:13;s:10:\"SHIN, D. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"584\";s:8:\"\u0000*\u0000epage\";s:3:\"590\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"LEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J.-L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"KANG, Y.-K\";i:1;s:9:\"RYU, M.-H\";i:2;s:11:\"CHANG, H. M\";i:3;s:9:\"KIM, T.-W\";i:4;s:10:\"BAEK, J. H\";i:5;s:9:\"MIN, Y. J\";i:6;s:10:\"KANG, H. J\";i:7;s:9:\"LEE, K.-H\";i:8;s:10:\"ZANG, D. Y\";i:9;s:10:\"RYOO, B.-Y\";i:10;s:9:\"KIM, J. G\";i:11;s:10:\"PARK, S. R\";i:12;s:10:\"KANG, W. K\";i:13;s:10:\"SHIN, D. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"584\";s:8:\"\u0000*\u0000epage\";s:3:\"590\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"LEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J.-L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"KANG, Y.-K\";i:1;s:9:\"RYU, M.-H\";i:2;s:11:\"CHANG, H. M\";i:3;s:9:\"KIM, T.-W\";i:4;s:10:\"BAEK, J. H\";i:5;s:9:\"MIN, Y. J\";i:6;s:10:\"KANG, H. J\";i:7;s:9:\"LEE, K.-H\";i:8;s:10:\"ZANG, D. Y\";i:9;s:10:\"RYOO, B.-Y\";i:10;s:9:\"KIM, J. G\";i:11;s:10:\"PARK, S. R\";i:12;s:10:\"KANG, W. K\";i:13;s:10:\"SHIN, D. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"584\";s:8:\"\u0000*\u0000epage\";s:3:\"590\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"LEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J.-L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"KANG, Y.-K\";i:1;s:9:\"RYU, M.-H\";i:2;s:11:\"CHANG, H. M\";i:3;s:9:\"KIM, T.-W\";i:4;s:10:\"BAEK, J. H\";i:5;s:9:\"MIN, Y. J\";i:6;s:10:\"KANG, H. J\";i:7;s:9:\"LEE, K.-H\";i:8;s:10:\"ZANG, D. Y\";i:9;s:10:\"RYOO, B.-Y\";i:10;s:9:\"KIM, J. G\";i:11;s:10:\"PARK, S. R\";i:12;s:10:\"KANG, W. K\";i:13;s:10:\"SHIN, D. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604536\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"584\";s:8:\"\u0000*\u0000epage\";s:3:\"590\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:3:\"LEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"J.-L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"KANG, Y.-K\";i:1;s:9:\"RYU, M.-H\";i:2;s:11:\"CHANG, H. M\";i:3;s:9:\"KIM, T.-W\";i:4;s:10:\"BAEK, J. H\";i:5;s:9:\"MIN, Y. J\";i:6;s:10:\"KANG, H. J\";i:7;s:9:\"LEE, K.-H\";i:8;s:10:\"ZANG, D. Y\";i:9;s:10:\"RYOO, B.-Y\";i:10;s:9:\"KIM, J. G\";i:11;s:10:\"PARK, S. R\";i:12;s:10:\"KANG, W. K\";i:13;s:10:\"SHIN, D. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:163:\"A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
